Clinical Trials Logo

Clinical Trial Summary

The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).


Clinical Trial Description

This research study looks to enroll as many people with LFS or TP53 gene variants as possible in order to: - Better estimate cancer risks in individuals with TP53 variants or LFS, which is a rare condition. - Learn the range of cancer risks linked to TP53 variants to help individuals and families to improve our ability to counsel patients and families about cancer risks more accurately. - Improve opportunities for cancer prevention, early detection, and treatment. - Learn more about the meaning of TP53 variants in the blood that are not inherited (e.g. ACE/CHIP and mosaicism). Study procedures will include: - Collecting information from the participant's medical record and short questionnaires. - Collecting blood, saliva, eyebrow hair and tumor tissue samples (optional). - Sharing study information with family members (optional). It is expected that about 1500 people will take part in this research study. Participants will be in this study until it closes or the participant withdraws consent. The National Cancer Institute is providing funding for part of this study and is considered a study sponsor. They will require that some of the genetic information be made available to the research community without personal identifying information. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04541654
Study type Observational [Patient Registry]
Source Dana-Farber Cancer Institute
Contact Judy E Garber, MD, MPH
Phone 617-632-5770
Email jegarber@partners.org
Status Recruiting
Phase
Start date September 15, 2020
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04367246 - Li-Fraumeni Syndrome/TP53 Biobank
Completed NCT01737255 - Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome
Recruiting NCT05126810 - Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling
Active, not recruiting NCT02950987 - Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes N/A
Enrolling by invitation NCT03176836 - Li-Fraumeni Syndrome Imaging Study N/A
Recruiting NCT01143454 - Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Completed NCT02289326 - Biomarker Monitoring in TP53 Mutation Carriers
Recruiting NCT04982744 - Registry of Li Fraumeni and Li Fraumeni Like Syndromes
Completed NCT01981525 - A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome Phase 1
Completed NCT00406445 - Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome
Recruiting NCT01443468 - Clinical and Genetic Studies of Li-Fraumeni Syndrome
Completed NCT04966923 - Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53
Recruiting NCT06088030 - Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer Phase 2
Recruiting NCT03050268 - Familial Investigations of Childhood Cancer Predisposition